Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumour-associated hypoglycaemia in a murine cachexia model.

T M McDevitt1, M J Tisdale

  • 1CRC Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.

British Journal of Cancer
|November 1, 1992
PubMed
Summary

Malignant cachexia induced by the MAC16 tumor caused progressive weight loss and decreased blood glucose in animals. The similar MAC13 tumor did not affect weight or blood glucose, indicating a specific tumor-induced metabolic alteration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia.

The Journal of frailty & aging·2016
Same author

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

British journal of cancer·2014
Same author

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Cell death and differentiation·2013
Same author

Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.

Cellular signalling·2012
Same author

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Leukemia·2011
Same author

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

British journal of cancer·2011

Area of Science:

  • Oncology
  • Metabolic Research
  • Cancer Biology

Background:

  • Cachexia is a complex metabolic syndrome often associated with cancer.
  • Understanding the mechanisms underlying cancer-induced cachexia is crucial for patient care.
  • Tumor type can significantly influence the host's metabolic response.

Purpose of the Study:

  • To investigate the metabolic effects of specific adenocarcinoma tumor models in animals.
  • To determine the relationship between tumor growth, body weight, and blood glucose levels.
  • To explore potential mechanisms behind tumor-induced metabolic alterations.

Main Methods:

  • Comparison of two adenocarcinoma tumor models (MAC16 and MAC13) in animals.
  • Monitoring of body weight and blood glucose levels during tumor growth.

Related Experiment Videos

  • Assessment of food intake and tumor glucose consumption.
  • Analysis of insulin-like growth factor (IGF-I and IGF-II) mRNA expression in tumor cells.

    • Main Results:

    • MAC16 adenocarcinoma induced progressive weight loss and decreased blood glucose levels.
    • MAC13 adenocarcinoma did not significantly alter body weight or blood glucose levels.
    • The observed hypoglycemia in MAC16-bearing animals was not attributed to reduced food intake, tumor glucose consumption, or increased IGF mRNA levels.

    Conclusions:

    • The MAC16 tumor actively induces a cachectic state with associated hypoglycemia.
    • The MAC13 tumor serves as a control, highlighting the specific nature of the MAC16 tumor's metabolic impact.
    • The precise mechanisms linking MAC16-induced cachexia and altered glucose metabolism require further investigation.